Track the companies that matter to you. It's FREE! Click one of these fan favorites to get started: Apple; Google; Ford.



Good News for Lucky Men

There's a new choice for treating erectile dysfunction, but the question investors should be asking is whether it'll increase sales of Eli Lilly's (NYSE: LLY  ) Cialis. The current dosage of Cialis has a 36-hour shot clock in which it works, but now the FDA has approved a low-dose version of the drug that can be taken once daily.

The ironic thing is that Eli Lilly only needed to get the approval because its drug lasts longer than its competitors'. Pfizer's (NYSE: PFE  ) Viagra and Levitra, which is marketed by GlaxoSmithKline (NYSE: GSK  ) , Schering-Plough (NYSE: SGP  ) , and Bayer, can be taken daily because they don't last as long, although there's no Food and Drug Administration approval for it.

The big question is whether the new dosage will increase sales of Cialis. Sales of the drug will likely go over $1 billion for the first time in 2007, but it still trails Viagra in total sales. The drugs may make patients blind or deaf, but men are still going to take them.

Eli Lilly is going to price a one-month supply of the once-a-day dose at about the same price as eight of the tablets that last 36 hours, so it may be that patients who are having sex more than twice a week will switch to the low-dose formula without any increase in revenue.

Whether Eli Lilly can convince men and their partners who like the idea of spontaneity to switch from rival products remains to be seen. But I can't wait to see the new advertisements.

Read/Post Comments (0) | Recommend This Article (3)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Compare Brokers

Fool Disclosure

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 558062, ~/Articles/ArticleHandler.aspx, 10/25/2016 4:53:41 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated Moments ago Sponsored by:
DOW 18,169.27 -53.76 -0.30%
S&P 500 2,143.16 -8.17 -0.38%
NASD 5,283.40 -26.43 -0.50%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

10/25/2016 4:00 PM
LLY $77.75 Up +0.18 +0.23%
Eli Lilly and Co. CAPS Rating: ***
GSK $40.32 Down -0.36 -0.88%
GlaxoSmithKline CAPS Rating: ***
PFE $32.28 Up +0.15 +0.47%
Pfizer CAPS Rating: ****
SGP.DL2 $28.15 Down +0.00 +0.00%
Schering-Plough Co… CAPS Rating: ****